The cannabis giant’s Wall Street honeymoon is getting a second act. Trulieve rang the NYSE closing bell on Tuesday to mark its landmark June 10 listing — the first-ever NYSE debut by a US cannabis company — but the ceremony landed amid a flurry of regulatory and operational developments that paint a far more complex picture than the celebration suggests.
The DEA’s Pivotal Shift
The most significant catalyst arrived in a filing dated August 17, when the Drug Enforcement Administration formally urged the presiding judge to reclassify cannabis from Schedule I — the most restrictive drug category — to the far more lenient Schedule III. The agency based its position on evidence gathered during a nearly three-week hearing that ran from June 29 to July 15.
Chief Administrative Law Judge Derek Julius now holds the pen. With closing arguments submitted, he must issue a recommendation before the DEA’s administrative wing renders a final verdict. No timeline has been attached to that process, leaving investors to weigh the potential upside against an open-ended wait.
The filing drew predictable pushback. Smart Approaches to Marijuana, the states of Idaho, Indiana, and Nebraska, the Tennessee Bureau of Investigation, the National Drug and Alcohol Screening Association, and several individual physicians all lodged objections.
Already Benefiting From a Narrower Rule
What complicates the narrative — and arguably strengthens Trulieve’s near-term position — is that a separate, more contained reclassification is already in effect. Since April 28, 2026, the DEA has placed cannabis in FDA-approved drugs and state-licensed medical marijuana under Schedule III. Trulieve’s post-restructuring operations consist precisely of such state-licensed medical businesses, meaning the company is already operating under the more favorable classification.
The current proceeding targets the broader recreational market. Success would carry industry-wide implications: the elimination of Section 280E from the US tax code, which currently bars cannabis companies from deducting ordinary business expenses, along with improved research access and softer federal oversight. Crucially, Schedule III status would not legalize state markets nor fully shield licensed operators from federal prosecution — a reality that tempers expectations of an immediate windfall.
A Quarter of Contradictions
The regulatory momentum builds on financial results that require careful parsing. Second-quarter revenue fell 10 percent year over year to $271 million, with a gross margin of 60 percent. The headline GAAP net loss of $406 million, however, was largely driven by a one-time, non-cash charge of $407 million tied to the deconsolidation of Harvest’s adult-use business.
Should investors sell immediately? Or is it worth buying Trulieve?
Strip that out, and the operating picture brightens considerably. Adjusted EBITDA reached $98 million, translating to a 36 percent margin, while adjusted net income came in at $20 million, or $0.11 per diluted share. First-half operating cash flow totaled $109 million, with free cash flow of $74 million. Management reaffirmed its 2026 guidance calling for at least $225 million in operating cash flow.
Analyst reactions split along familiar lines. Alliance Global Partners reiterated its buy rating on August 7 while lifting its price target from $19.00 to $20.00. Cantor Fitzgerald held its “Overweight” stance the same day, keeping a $15.00 target.
Structural Moves and a Texas Bet
Beyond the numbers, Trulieve has been reshaping its corporate architecture. The redomiciliation from British Columbia to Delaware closed on August 11, following shareholder approval on August 5 and a final order from British Columbia’s Supreme Court on August 10. That same day, CEO Kim Rivers disclosed the termination of her pre-arranged trading plan under Rule 10b5-1, after an initial tranche of 1,699,007 voting common shares was sold in June.
Texas represents the next growth frontier. The company reports its initial production capacity is ready for final inspection, with a distribution pipeline spanning all eleven public health regions of the Texas Compassionate Use Program. The Department of Public Safety must still complete due diligence and inspections before Trulieve TX can convert its conditional license into full operational status — a process without a publicly stated completion date.
On the federal compliance front, all 207 medical dispensaries are now registered with the DEA following the April rescheduling, with inspections finished in Florida, Pennsylvania, and West Virginia.
What the Market Is Watching
The stock has climbed roughly 29 percent over the past month, reflecting growing conviction that the regulatory pendulum is swinging in the industry’s favor. Trulieve remains the largest holding in the AdvisorShares Pure US Cannabis ETF at about 30 percent of total assets, tying its share price closely to sector-wide sentiment.
The coming weeks are likely to be driven by regulatory headlines rather than operational updates. The evidence is gathered, the briefs are filed, and the ball sits with Judge Julius. For investors, the calculus is straightforward: the potential payoff of full tax relief is substantial, but the timing of a final DEA decision remains stubbornly uncertain.
Ad
Trulieve Stock: Buy or Sell?! New Trulieve Analysis from August 22 delivers the answer:
The latest Trulieve figures speak for themselves: Urgent action needed for Trulieve investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from August 22.
Trulieve: Buy or sell? Read more here...
